Articles

█ For kidney cancer, ESMO 2026 has one of its most concentrated programmes in years. Nearly all of the practice-relevant renal data come on a single day, Sunday, October 25. The morning Proffered Paper session puts both phase 3 belzutifan readouts, a…

#Equal Contributions as Senior/Supervising Authors ϮAddress Correspondence: Abhishek A. Chakraborty, PhD Department of Cancer Sciences, Cleveland Clinic, Cleveland OH E-mail: chakraa@ccf.org Conflict of Interest: The authors declare no conflict of interest with this study. INTRODUCTION Clinical outcomes for patients…

Perspectives synthesized from ASCO 2026 presenter and discussant sessions and post-meeting expert commentary. Prepared for educational purposes by the Kidney Cancer Journal editorial team. Toni K. Choueiri, MD, FASCO. Dana-Farber Cancer Institute, Boston, MA. Presenter — LITESPARK-022 and KEYNOTE-564 ctDNA Analysis…

Thank you for subscribing to the Kidney Cancer Journal.  You're now part of a community dedicated to advancing research, treatment, and hope.  We'll be in touch soon